Results 101 to 110 of about 22,609,350 (346)

Supplementary Figure S6: Ipilimumab does not deplete CD4+CTLA-4+FOXP3+ Tregs from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3⁺ Regulatory T Cells (Tregs) in Human Cancers

, 2019
Tumor infiltrating cells from paired melanoma tissue (N=5 pre-Ipi; N=5 post-Ipi) were analyzed by CyTOF. The impact of ipilimumab on the intratumoral frequency of A) CD3+CD4+FOXP3+CTLA-4+ (Tregs), B) CD3+CD4+FOXP3-CTLA-4+ T cells, and C) CD3+CD4+FOXP3 ...
Padmanee Sharma (8133285), Jorge Blando (8133276), Jennifer Wargo (3536045), Jorge Scutti (15010292), James P. Allison (15010295), Antoni Ribas (49231), Anu Sharma (4976), Sumit K. Subudhi (14992022), Luis Vence (312988)   +8 more
core   +1 more source

Targeting Lactate‐Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
Tumor‐derived lactate activates PSCs through MCT1‐mediated Vps34 lactylation and autophagy. These activated PSCs secrete CXCL9/10, upregulating PD‐1 on CD8+ T cells via the CXCR3/STAT3 axis to foster immunosuppression. Disrupting this metabolic crosstalk by targeting MCT1 effectively sensitizes pancreatic cancer to PD‐1 blockade, presenting a promising
Wenfeng Zhuo, Rong Hu, Yuhang Hu, Ping Hu, Shengbo Han, Guozheng Lv, Zhu Zeng, Yong Zhao, Yang Li, Yan Huang, Yingsong Zhao, Hongda Wang, Guangyu Zhao, Eryang Zhao, Gang Zhao   +14 more
wiley   +1 more source

CD28-Dependent CTLA-4 Expression Fine-Tunes the Activation of Human Th17 Cells

iScience, 2020
Summary: Previous work has demonstrated that Th17 memory cells but not Th1 cells are resistant to CD28/CTLA-4 blockade with CTLA-4 Ig, leading us to investigate the individual roles of the CD28 and CTLA-4 cosignaling pathways on Th1 versus Th17 cells. We
Scott M. Krummey, Christina R. Hartigan, Danya Liu, Mandy L. Ford   +3 more
doaj   +1 more source

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Science Translational Medicine, 2017
Profiling of melanoma patients treated with checkpoint blockade reveals TCR clonality and copy number loss as correlates of therapeutic response. Checking on checkpoint inhibitors Immune checkpoint blockade has greatly improved the success of treatment ...
Whijae Roh, Pei-Ling Chen, A. Reuben, C. Spencer, P. Prieto, John P Miller, V. Gopalakrishnan, Feng Wang, Z. Cooper, S. Reddy, C. Gumbs, L. Little, Qing Chang, Wei-Shen Chen, K. Wani, M. P. de Macedo, Eveline Chen, J. Austin-Breneman, Hong Jiang, J. Roszik, M. Tetzlaff, M. Davies, J. Gershenwald, H. Tawbi, A. Lazar, P. Hwu, W. Hwu, A. Diab, I. Glitza, S. Patel, S. Woodman, R. Amaria, V. Prieto, Jianhua Hu, Padmanee Sharma, J. Allison, L. Chin, Jianhua Zhang, J. Wargo, P. Futreal   +39 more
semanticscholar   +1 more source

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Nature Communications, 2020
Gut microbiota composition influences the clinical benefit of immune checkpoints in patients with advanced cancer but mechanisms underlying this relationship remain unclear. Molecular mechanism whereby gut microbiota influences immune responses is mainly
C. Coutzac, J. Jouniaux, A. Paci, J. Schmidt, D. Mallardo, A. Seck, V. Asvatourian, L. Cassard, P. Saulnier, L. Lacroix, P. Woerther, A. Vozy, M. Naigeon, L. Nebot-Bral, M. Desbois, E. Simeone, C. Mateus, L. Boselli, J. Grivel, E. Soularue, P. Lepage, F. Carbonnel, P. Ascierto, C. Robert, N. Chaput   +24 more
semanticscholar   +1 more source

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Cancers, 2021
Simple Summary In the fight against cancer, immunotherapies have given great hope after encouraging results in clinical investigations showing complete remission in some patients with melanoma. In fact, directing the immune system against cancer has been
N. Sobhani, Dana Rae Tardiel-Cyril, Aram Davtyan, D. Generali, R. Roudi, Yong Li   +5 more
semanticscholar   +1 more source

CTLA-4+49 A/G polymorphism and antiglutamic acid decarboxylase antibody-associated encephalopathy in Taiwanese children

, 2017
Background: Anti-glutamic acid decarboxylase antibodies are associated with encephalopathy, an autoimmune central nervous system inflammatory disease. The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)+49 A/G polymorphism has been shown to confer ...
Lin, Jainn-Jim;Lin, Kuang-Lin;Wang, Yu;Wang, Huei-Shyong;Hsia, Shao-Hsuan;Chang, Luan-Yin, 張鑾英   +1 more
core   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

Advanced Science, EarlyView.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao, Zhenyang Ren, Jing Zhou, He Luo, Yuling Li, Dan Chen, Yuxiao Jiang, Canzhe Li, Mengyi Zheng, Anqi Li, Yao Wang, Yang Zhang, Dingye Wang, Yanjun Jiang, Jiangyong Gu, Biaoyan Du, Yafei Shi, Fang Liu, Jianyong Xiao, Kun Wang   +19 more
wiley   +1 more source

Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction

Cell Reports
Summary: The CTLA-4 and PD-1 checkpoints control immune responses and are key targets in immunotherapy. Both pathways are connected via a cis interaction between CD80 and PD-L1, the ligands for CTLA-4 and PD-1, respectively. This cis interaction prevents
Maximillian A. Robinson, Alan Kennedy, Carolina T. Orozco, Hung-Chang Chen, Erin Waters, Dalisay Giovacchini, Kay Yeung, Lily Filer, Claudia Hinze, Christopher Lloyd, Simon J. Dovedi, David M. Sansom   +11 more
doaj   +1 more source

Role of the Crosstalk Between CTLA-4 and NKG2D in the Development of Anti-CTLA-4 Treatment Strategies

Immunotherapy, 2013
Results of immunotherapy trials targeting co inhibitory receptors on T cells show that interfering with suppressive pathways can trigger antitumor activity even at advanced disease stages [1]. Proof has been obtained in Phase III trials that treatment with antibodies blocking CTLA-4 extends survival of metastatic melanoma patients.
Demaria, S, Dustin, M
openaire   +3 more sources